• Clinicopathological factors associated with death from thin (</=1.00mm) melanoma

      Claeson, M; Baade, P; Brown, S; Soyer, HP; Smithers, BM; Green, Adèle C; Whiteman, DC; Khosrotehrani, K; Department of Population Health, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia (2019)
    • Early detection of melanoma: a consensus report from the Australian Skin and Skin Cancer Research Centre Melanoma Screening Summit

      Janda, M; Cust, AE; Neale, RE; Aitken, JF; Baade, PD; Green, Adèle C; Khosrotehrani, K; Mar, V; Soyer, HP; Whiteman, DC; et al. (2020)
    • Extreme incidence of skin cancer in kidney and liver transplant recipients living with high sun exposure

      Plasmeijer, EI; Jiyad, Z; Way, M; Marquart, L; Miura, K; Campbell, S; Isbel, N; Fawcett, J; Ferguson, LE; Davis, M; et al. (2019)
    • Long-term deaths from melanoma according to tumor thickness at diagnosis

      Baade, PD; Whiteman, DC; Janda, M; Cust, AE; Neale, RE; Smithers, BM; Green, Adèle C; Khosrotehrani, K; Mar, V; Soyer, HP; et al. (2020)
      There is little long-term follow-up information about how the number of melanoma deaths and case fatality vary over time according to the measured thickness of melanoma at diagnosis. This population-based longitudinal cohort study examines patterns and trends in case fatality among 44,531 people in Queensland (Australia) diagnosed with a single invasive melanoma (International Classification of Diseases for Oncology, third revision [ICD-O-3], C44, Morphology 872-879) between 1987 and 2011, including 11,883 diagnosed between 1987 and 1996, with up to 20 years follow-up (to December 2016). The 20-year case fatality increased by thickness, with the percentage of melanoma deaths within 20 years of diagnosis being up to 4.8% for melanomas with measured thickness <0.80 mm, 10.6% for tumors 0.8 to <1.0 mm and generally more than 30% for melanomas measuring 3 mm and more. For melanomas <1.0 mm, most deaths occurred between 5 and 20 years after diagnosis, whereas for thicker melanomas the reverse was true with most deaths occurring within the first 5 years. Five-year case fatality decreased over successive calendar time periods for melanomas <1.0 mm, but not for melanomas ≥1.0 mm. These findings demonstrate that the time course for fatal melanomas varies markedly according to tumor thickness at diagnosis. Improved understanding of the patient factors and characteristics of melanomas, in addition to tumor thickness, which increase the likelihood of progression, is needed to guide clinical diagnosis, communication with patients and ongoing surveillance pathways of patients with potentially fatal lesions.
    • Self-reported naevus density may lead to misclassification of melanoma risk

      Betz-Stablein, B; Koh, U; Plasmeijer, E; Janda, M; Aitken, JF; Soyer, HP; Green, Adèle C; Cancer and Population studies, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia (2019)
    • Skin cancer multiplicity in lung transplant recipients: prospective, population-based study

      Way, M; Marquart, L; Chambers, DC; Hopkins, P; Miura, K; Jiyad, Z; Plasmeijer, EI; Ferguson, LE; Davis, M; Whiteman, DC; et al. (2019)
      BACKGROUND: Lung transplant recipients are at high risk of skin cancer but precise annual incidence rates of treated skin cancers per patient are unknown. OBJECTIVES: To prospectively assess the total burden of histologically confirmed squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) and associated factors in lung transplant recipients. METHODS: A population-based cohort of 125 Queensland lung transplant recipients aged 18 years and over, recruited 2013 - 2015, were followed to the end of 2016. All underwent dermatologic skin examinations at baseline and annually thereafter and patients self-reported all interim treated skin cancers which were verified against pathology databases. Standard skin cancer risk factors were obtained via questionnaire, and medications from hospital records. RESULTS: During a median follow-up time of 1.7 years, 29 (23%) and 30 (24%) lung transplant recipients with median duration of immunosuppression 3.3 years, developed SCC and BCC respectively. General population age-standardized incidence rates of SCC and BCC were 201 and 171 per 1000 person-years respectively (based on first primary SCC or BCC during follow-up), but on accounting for multiple primary tumours, corresponding incidence rates were 447 and 281 per 1000 person-years. Risk of multiple SCCs increased around 6-fold in those aged 60+ and in those with previous skin cancer and increased around 3-fold in those treated with the antifungal voriconazole. Multiple BCC risk rose 3-fold from age 60 years and 10-fold with previous skin cancer. CONCLUSIONS: Lung transplant recipients have very high incidence of multiple primary skin cancers. Close surveillance and assiduous prevention measures are essential.